AutoGenomics announced Nov. 2 the release of a series of pharmacogenetic ASRs, including CYP 450 2C9 / VKORC1, which can be used to assess warfarin sensitivity.
Other applications for the new ASRs include CYP 450 2D6, 2C19, NAT2, UGT1A1, MDR1 and 3A4/3A5 tests.
AutoGenomics CEO Fareed Kureshy touted the achievement as “the most comprehensive panel of ASRs made available by any company” and said the achievement positioned the company as a leader in personalized medicine.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.